DAVITA INC. DVA

DaVita’s strongest current rail is still the official first-quarter filing. For the period ending March 31, 2026, the company reported revenues of $3.42 billion, operating income of $481.9 million, net income attributable to parent of $197.5 million and diluted earnings per share of $2.87, according to its SEC EDGAR 10-Q. That gives the file a real operating base before the newer June filing trail enters the frame.

DaVita is being read here as an operating healthcare company, not a ticker floating loose from its service reality. The supplied 10-Q evidence points directly to dialysis patient service revenues of $3,272,797 for the three months ended March 31, 2026, compared with $3,102,993 in the comparable 2025 line supplied in the filing extract. The core business evidence is therefore patient service revenue, clinic economics, payor collection, capital spending and cash generation, rather than a product launch story or a speculative pipeline claim.

The filed financial picture is mixed in a useful, traceable way. DaVita reported assets of $17.50 billion, liabilities of $16.45 billion, stockholders’ equity attributable to parent of negative $755.5 million, cash and cash equivalents of $644.2 million, net cash provided by operating activities of $320.8 million, and payments to acquire property, plant and equipment of $102.0 million for the 10-Q period ending March 31, 2026. Inventory was $141.6 million, with an increase or decrease in inventories of negative $20.3 million, and diluted weighted average shares outstanding were 68.9 million.

The supplied source pack does not include a chart route, quoted share price, candle pattern, volume figure or technical level, so the market mechanism should stay on the SEC rail: quarterly operating results, balance sheet leverage, cash conversion, capital spending and follow-on filings. Any visual chart carried by the renderer should be treated as context only unless a priced chart source is separately supplied.

The named June developments are filing trail-heavy but still relevant. SEC EDGAR lists two Form 4 filings dated June 17, 2026, an 11-K filed on June 17, 2026, and Form 144 filings dated June 16 and June 15. The 11-K states that during the year ended December 31, 2025, the Plan made purchases of approximately $6,807 and sales of approximately $11,831 of DaVita Inc. Those plan figures are small beside the operating company, but they add a clean governance and ownership-process note to the daily file.

The 8-K dated May 5, 2026 says DaVita issued a press release announcing financial results for the quarter ended March 31, 2026. The evidence supplied here does not parse guidance, dividend policy, new debt terms, clinic count, treatment volume, reimbursement changes or management commentary. That absence matters because the current report can prove earnings, cash, capital spending and filing activity, but it cannot fairly turn them into a forecast.